AstraZeneca, Rigel ink $1.25 bln drug pact
February 16, 2010 at 03:35 AM EST
AstraZeneca reaches a deal to pay Rigel Pharmaceuticals up to $1.25 billion before royalties to license a drug used to treat rheumatoid arthritis.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|